Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms

Alexander Röntgen, Zenon Toprakcioglu, James E. Tomkins, Michele VendruscoloProceedings of the National Academy of Sciences 2024 · DOI

TL;DR

This study investigates how different versions of the α-synuclein protein, created through alternative splicing, affect its aggregation. They found that certain isoforms (αSyn-112 and αSyn-98) aggregate much faster and form different structures than the most common form (αSyn-140). Crucially, even small amounts of αSyn-112 can significantly speed up the aggregation of αSyn-140, suggesting alternative splicing plays a key role in the development of neurodegenerative diseases like Parkinson's.

What Problem Does This Paper Address?

Parkinson's disease (PD) and other synucleinopathies are characterized by the misfolding and aggregation of a protein called α-synuclein (aSyn). Understanding the precise mechanisms behind this aggregation is vital for developing effective treatments. While the most abundant form of aSyn is a 140-amino acid protein (aSyn-140), the gene encoding it (SNCA) can produce several other versions, known as isoforms, through alternative splicing. These isoforms differ in length due to the skipping of specific exons. This paper addresses the question of whether these different aSyn isoforms, with their altered sequences, have distinct aggregation behaviors and if they can influence the aggregation of the primary aSyn-140 form. This is important because the presence and behavior of these less-studied isoforms might contribute to the complex pathology of synucleinopathies.

Methods

The researchers employed a multi-pronged approach to characterize the aggregation of the four main aSyn isoforms (aSyn-140, aSyn-126, aSyn-112, and aSyn-98):

  • Recombinant Protein Production and Purification: They expressed and purified each aSyn isoform to high purity.
  • Aggregation Kinetics Assays: Thioflavin T (ThT) fluorescence intensity was measured over time to monitor the formation of amyloid fibrils. This is a standard method for tracking protein aggregation.
  • Kinetic Modeling: The aggregation data was analyzed using the AmyloFit platform to derive microscopic rate constants and determine the underlying aggregation mechanisms. This allowed for a quantitative comparison of aggregation speeds and pathways.
  • Transmission Electron Microscopy (TEM): TEM was used to visualize the morphology of the aggregates formed by each isoform and their mixtures. This technique provides high-resolution images of the fibrillar structures.
  • Cell Viability Assays (MTT Assay): SH-SY5Y neuroblastoma cells were treated with the different aSyn aggregates to assess their cytotoxic effects, providing insight into the potential disease relevance of these aggregates.
  • Co-aggregation and Cross-seeding Experiments: These experiments investigated how different isoforms interact during aggregation, either by mixing monomers or by using pre-formed fibrils of one isoform to seed the aggregation of another.

Datasets

Not discussed in the paper. The study relies on in vitro experiments and cell culture models.

Key Insights and Ideas

  • Alternative Splicing Creates "Aggregative" Isoforms: The study reveals that skipping exon 5 (leading to aSyn-112 and aSyn-98) significantly accelerates aSyn aggregation compared to the full-length aSyn-140. This suggests that the C-terminal region, which is truncated in these isoforms, plays a crucial role in preventing aggregation.
  • Distinct Aggregate Architectures: The faster-aggregating isoforms (aSyn-112 and aSyn-98) don't just aggregate faster; they form morphologically distinct structures. Instead of elongated fibrils, they form "clumps" of interconnected fibrils, suggesting a different assembly pathway.
  • "Seeding" the Problem: Even small amounts of the more aggregative aSyn-112 can dramatically speed up the aggregation of the less aggregative aSyn-140. This "cross-talk" between isoforms highlights how the cellular environment, with its mix of isoforms, could be primed for pathological aggregation.
  • Cellular Toxicity is Isoform-Dependent (and Complex): While aggregates of all isoforms showed some toxicity, the faster-aggregating aSyn-112 and aSyn-98 aggregates were less toxic in cell culture assays. This is counterintuitive but might be explained by their clumped morphology, making them less accessible to cells. However, this contrasts with some other studies, suggesting the context (e.g., intracellular vs. extracellular, monomer vs. aggregate) is critical.

Key Results

  • Accelerated Aggregation: aSyn-112 and aSyn-98 aggregated significantly faster than aSyn-140 and aSyn-126. The aggregation half-time (t1/2) was reduced by orders of magnitude for aSyn-112 and aSyn-98.
  • Morphological Differences: TEM images showed that aSyn-140 and aSyn-126 formed elongated amyloid fibrils, while aSyn-112 and aSyn-98 formed distinct, clumped structures. Fibril widths also differed, with aSyn-112 and aSyn-98 fibrils being narrower.
  • Synergistic Aggregation: Co-incubation of 90% aSyn-140 with 10% aSyn-112 monomers led to a ~25% decrease in the aggregation half-time of aSyn-140, demonstrating a significant acceleration effect.
  • Reduced Cross-seeding Efficiency: Pre-formed fibrils of aSyn-126, aSyn-112, and aSyn-98 were less efficient at seeding aSyn-140 aggregation compared to aSyn-140 self-seeding, with aSyn-98 being the least efficient.
  • Differential Cell Viability: At high concentrations (2 µM), all aggregates reduced cell viability by ~30%. However, at lower concentrations (0.02 µM and 0.002 µM), aggregates of aSyn-112 and aSyn-98 showed significantly less toxicity than those of aSyn-140 and aSyn-126.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted in vitro. While it provides mechanistic insights, the behavior of these isoforms in a complex cellular and in vivo environment might differ. The authors suggest future experiments using in vivo models of aSyn aggregation are needed.
  • Cellular Context: The cell viability results for aSyn-112 and aSyn-98 aggregates being less toxic than aSyn-140 aggregates is noted as potentially contrasting with other studies, highlighting the importance of experimental context.
  • Lipid Interactions: The paper mentions that exon 3 deletion might modulate aggregation in the presence of lipids, but this was not directly tested in this study. Future work could explore the role of lipids in isoform-specific aggregation.
  • Proteomic Detection: The authors note that detecting these isoforms at the protein level can be challenging, suggesting that advancements in antibody or proteomic approaches will be valuable for future research.

Summary updated

Abstract

The misfolding and aggregation of α-synuclein is linked to a family of neurodegenerative disorders known as synucleinopathies, the most prominent of which is Parkinson's disease (PD). Understanding the aggregation process of α-synuclein from a mechanistic point of view is thus of key importance. <i>SNCA</i>, the gene encoding α-synuclein, comprises six exons and produces various isoforms through alternative splicing. The most abundant isoform is expressed as a 140-amino acid protein (αSyn-140), while three other isoforms, αSyn-126, αSyn-112, and αSyn-98, are generated by skipping exon 3, exon 5, or both exons, respectively. In this study, we performed a detailed biophysical characterization of the aggregation of these four isoforms. We found that αSyn-112 and αSyn-98 exhibit accelerated aggregation kinetics compared to αSyn-140 and form distinct aggregate morphologies, as observed by transmission electron microscopy. Moreover, we observed that the presence of relatively small amounts of αSyn-112 accelerates the aggregation of αSyn-140, significantly reducing the aggregation half-time. These results indicate a potential role of alternative splicing in the pathological aggregation of α-synuclein and provide insights into how this process could be associated with the development of synucleinopathies.
BibTeX
@inproceedings{rontgen2024modulation,
  author = {Alexander Röntgen and Zenon Toprakcioglu and James E. Tomkins and Michele Vendruscolo},
  title = {{Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2313465121},
}
Figure